Billion Cell Atlas adds three AI drug developers to genome research alliance

Illumina announced an expansion of the Billion Cell Atlas, a collaborative research platform that launched in January 2026 with founding members AstraZeneca, Merck, and Eli Lilly and Company. The alliance has now added three new member companies, including Formation Bio, along with two additional AI-driven drug discovery partners, reflecting growing confidence in the platform's value for next-generation drug development.

The Atlas operates on an unprecedented scale. Over 350 million cells have been sequenced to date, generating upwards of six petabytes of genomic data. The core mechanism uses CRISPR gene editing to capture how one billion individual cells respond to genetic changes across more than 200 disease-relevant cell lines. This approach enables member companies to accomplish several objectives: discovering and validating novel drug targets, characterizing the mechanisms by which drugs and diseases work, and exploring potential new indications for existing therapies.

The breadth and diversity of the dataset—spanning hundreds of disease-relevant and healthy cell types—is designed to reveal fundamental insights into how diseases originate, develop, and potentially progress. According to the announcement, upon completion, the Billion Cell Atlas will be the most comprehensive map of human disease biology. Illumina describes it as the world's largest genome-wide genetic perturbation dataset, positioning the collaborative resource as critical infrastructure for AI-driven drug discovery teams seeking to accelerate the development of novel therapeutics.

The Billion Cell Atlas represents a significant collaboration in precision medicine infrastructure, bringing together major pharmaceutical companies and specialized AI drug discovery firms around a shared genomic resource. Launched just months ago in January 2026, the alliance has already grown from its three founding members (AstraZeneca, Merck, and Eli Lilly and Company) to include Formation Bio and two additional AI-driven drug discovery partners, signaling strong industry momentum. The scale of the undertaking—over 350 million sequenced cells and upwards of six petabytes of data—positions the Atlas as the world's largest genome-wide genetic perturbation dataset, a foundation that enables member companies to move beyond traditional target discovery into understanding the mechanisms that underlie disease progression. By mapping how cells respond to genetic perturbations via CRISPR across more than 200 disease-relevant cell lines, the alliance aims to create what it describes as the most comprehensive map of human disease biology, a resource that could accelerate the identification of novel therapeutic pathways and potentially open avenues for disease reversal.

No comments yet. Be the first to share your thoughts!